Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Rate this post




AEAVEX Life Sciences announce the results of up to 4 years of oral Blaclamesine about the experience of extending IIB / III open label, Alzheimer’s early morning

 
Report

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *